Loading...
XNAS
AZYO
Market cap33mUSD
Sep 06, Last price  
1.49USD
Name

Aziyo Biologics Inc

Chart & Performance

D1W1MN
P/E
P/S
0.99
EPS
Div Yield, %
Shrs. gr., 5y
22.20%
Rev. gr., 5y
-10.69%
Revenues
24m
-1.50%
39,038,00042,901,00042,682,00047,390,00023,849,00024,745,00024,375,000
Net income
-54m
L+43.27%
-11,566,000-11,939,000-21,825,000-24,832,000-32,897,000-37,656,000-53,949,000
CFO
-23m
L+4.12%
-5,125,000-8,446,000-13,435,000-15,618,000-21,902,000-21,761,000-22,657,000
Earnings
Jul 28, 2025

Profile

Aziyo Biologics, Inc., a regenerative medicine company, focuses on the development of regenerative medical products to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. It offers CanGaroo that combines the envelope with antibiotics and is designed to reduce the risk of infection following surgical implantation of an electronic device. The company also provides cardiovascular products, such as ProxiCor for use as an intracardiac patch or pledget for tissue repairs; Tyke for use in neonates and infants to repair pericardial structures; and VasCure, a patch material to repair or reconstruct the peripheral vasculature, including the carotid, renal, iliac, femoral, and tibial blood vessels for cardiovascular, vascular, and general surgeons. In addition, it offers Fiber VBM, ViBone, and OsteGro V that are human tissue-derived bone allografts designed to protect and preserve native bone cells; and SimpliDerm, a pre-hydrated HADM designed to repair or replacement of damaged or inadequate integumental tissues. Further, the company provides contract manufacturing services for various products to corporate customers. It sells its products to hospitals and other healthcare facilities through its direct sales force, commercial partners, and independent sales agents. The company was incorporated in 2015 and is headquartered in Silver Spring, Maryland.
IPO date
Oct 08, 2020
Employees
151
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑12
Income
Revenues
24,375
-1.50%
24,745
3.76%
23,849
-49.68%
Cost of revenue
48,658
45,282
53,838
Unusual Expense (Income)
NOPBT
(24,283)
(20,537)
(29,989)
NOPBT Margin
Operating Taxes
7
28
34
Tax Rate
NOPAT
(24,290)
(20,565)
(30,023)
Net income
(53,949)
43.27%
(37,656)
14.47%
(32,897)
32.48%
Dividends
Dividend yield
Proceeds from repurchase of equity
12,390
10,085
10,484
BB yield
Debt
Debt current
1,710
3,871
9,222
Long-term debt
29,399
25,991
30,408
Deferred revenue
Other long-term liabilities
16,076
13,275
1,083
Net debt
17,870
10,586
22,641
Cash flow
Cash from operating activities
(22,657)
(21,761)
(21,902)
CAPEX
(346)
(540)
Cash from investing activities
(474)
14,208
(540)
Cash from financing activities
17,094
9,840
9,003
FCF
(23,193)
(12,549)
(20,667)
Balance
Cash
13,239
19,276
16,989
Long term investments
Excess cash
12,020
18,039
15,797
Stockholders' equity
(229,558)
(175,621)
(137,972)
Invested Capital
229,600
180,158
173,420
ROIC
ROCE
EV
Common stock shares outstanding
29,071
18,161
13,833
Price
Market cap
EV
EBITDA
(20,832)
(16,789)
(26,423)
EV/EBITDA
Interest
4,779
5,796
5,118
Interest/NOPBT